Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Epithelial Ovarian Cancer Clinical Trials

6 recruiting trials for Epithelial Ovarian Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
6
Total Trials
6
Recruiting Now
2
Phase 3 Trials
6
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT05172310

PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI

Cancers of the pancreas, bile ducts, stomach and ovaries are dismal diseases with most patients being diagnosed in advanced stages leading to a bad prognosis. These cancers can be...

Sponsor: Karolinska University HospitalEnrolling: 4101 location
RECRUITINGPhase 3NCT07218809

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian...

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade,...

Sponsor: AstraZenecaEnrolling: 110020 locations
RECRUITINGNCT05236686

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian...

Sponsor: Shanghai Gynecologic Oncology GroupEnrolling: 941 location
RECRUITINGNCT04665635

Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery

Ovarian cancer is the most common cause of death in gynecological cancer. Approximately 75% of epithelial ovarian cancers are detected at an advanced stage. Metastasis and spread...

Sponsor: Cukurova UniversityEnrolling: 1202 locations
RECRUITINGPhase 3NCT06915025

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant...

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Sponsor: ImunonEnrolling: 5007 locations
RECRUITINGPhase 1NCT06756035

CT-95 in Advanced Cancers Associated With Mesothelin Expression

This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting...

Sponsor: Context Therapeutics Inc.Enrolling: 708 locations